Totally agree. With the utmost respect to fellow posters, there’s no way this company would get taken over for $25. I’m reasonably confident Neuren management values the business in line with what a few of us here (and Karst) do which is $2.-2.5 billion with trofinetide only. With the company on the cusp of FDA approval would they sell for the base price without a 30-40% premium or to add a premium for NNZ-2591? It’s highly doubtful. If I didn’t know anything about the drugs, TAMs, further applicable indications etc then I’d probably be quite happy with $25. But based on what I do know, and sure as hell Neuren knows a lot more than I do, $25 would be a fire sale and Neuren or the big wigs won’t bite. I’m happy knowing that.
Share Price, page-1795
-
- There are more pages in this discussion • 8,980 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$21.27 |
Change
0.650(3.15%) |
Mkt cap ! $2.718B | |||
| Open | High | Low | Value | Volume |
| $20.84 | $21.56 | $20.76 | $7.760M | 364.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1378 | $21.24 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $21.29 | 218 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| NEU (ASX) Chart |